Loading…
← CockpitCompetitor Analysis › 1873.HK Viva Biotech HoldingsOpen in the cockpit ↗

Viva Biotech Holdings1873.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum weak 36
Mkt cap
$303M
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$542,608
20-day average traded
Fwd P/E
8.1×
forward earnings
ROIC−WACC
-7.7 pp
WACC 11.7%
Hurdle
-17 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · HKDHK$1.17
1D0.0%
1W-10.3%
1M-14.6%
3M-19.3%
6M-18.2%
YTD-35.0%
1Y-44.5%
ATR %5.8%
52w lowhigh59.1% off high

What Viva Biotech does

Employees: 2,169

Viva Biotech at a glance

Size Viva Biotech (1873.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $303M, the 882nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$1.17 on 18 Nov 2026.

Performance Over six months the shares fell 18.2%, against -31.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 7.4% over the last twelve months (peer median +5.7%); the operating margin is 9.9% (peer median -244.5%).

Valuation It trades at 8.1× forward earnings.

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -17 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.7 points below its cost of capital (11.7% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20261873.HK 81Peer median 69
Six months, rebased to 100: Viva Biotech against the median of its 20 peers (local-currency closes).

Viva Biotech financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$2.13BHK$1.88BHK$2.15BHK$2.38BHK$2.77B
Revenue growth—-13%-10%-14%—
Gross profitHK$736MHK$711MHK$745MHK$816MHK$949M
EBITDAHK$440MHK$438MHK$481MHK$446MHK$525M
Net incomeHK$199MHK$238MHK$181M-HK$128M-HK$615M
Free cash flowHK$323MHK$98.0MHK$162MHK$187MHK$80.4M
Capital expenditureHK$168MHK$133MHK$208MHK$193MHK$271M
Total debtn/aHK$1.48BHK$1.37BHK$2.10BHK$3.17B

Quarterly statements and history in the cockpit →

Viva Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%XFORGLSIGALT4894NAUTPROK76306945CCCC21053880LRMR358570LYEL086900CRMDCTNM4760601873.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Viva Biotech is the large dot.

Fundamentals: revenue growth against valuation

+5%+10%10×15×38800869001873.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Viva Biotech is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%+600%0%250%500%750%0869004760601873.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Viva Biotech is the large dot.

Viva Biotech competitors and peer comparison

How Viva Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Viva Biotech against its 20 peers (data as of 18 Nov 2026)
Measure1873.HKPeer medianRank in peer set
1-month return-14.6%-4.7%6th lowest of 20
6-month return-18.2%-31.0%6th highest of 20
Distance from 52-week high-59.1%-52.1%8th lowest of 20
Revenue growth (TTM)+7.4%+5.7%6th highest of 13
Operating margin9.9%-244.5%4th highest of 15
Forward P/E8.1×n/a—
Growth the price implies (Req g, 7 yrs)2.6%n/a—
Growth delivered (Del g)+19.1%n/a—
Hurdle (Req g minus delivered)-16.5 ppn/a—
ROIC minus cost of capital-7.7 pp-63.8 pp5th highest of 14
EV / EBITDA5.0×12.4×2nd cheapest of 6
Net debt / EBITDA-0.4×-3.5×2nd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%8.1×2.6%+19.1%
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%n/an/an/a
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%n/an/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%n/an/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%n/an/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%n/an/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%n/an/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%n/an/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%10.5×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%n/an/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%n/an/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%18.1×4.7%+11.9%
CorMedix CRMDUnited States$358M-43%+92%39%n/an/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%n/a0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%n/an/an/a

Questions

Which companies are Viva Biotech's closest peers?
The cockpit's peer set: X4 Pharmaceuticals (XFOR), Greenwich LifeSciences (GLSI), Galectin Therapeutics (GALT), Cuorips (4894.T), Nautilus Biotechnolgy (NAUT), ProKidney (PROK), IMPACT Therapeutics (7630.HK), AP Biosciences (6945.TWO).
How has Viva Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -18.2% against -31.0% for the median peer; over one year -44.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.